nodes	percent_of_prediction	percent_of_DWPC	metapath
Albendazole—ABCB1—Mitomycin—urinary bladder cancer	0.179	0.317	CbGbCtD
Albendazole—CYP3A4—Thiotepa—urinary bladder cancer	0.0814	0.144	CbGbCtD
Albendazole—ABCB1—Gemcitabine—urinary bladder cancer	0.0516	0.0912	CbGbCtD
Albendazole—CYP1A2—Fluorouracil—urinary bladder cancer	0.0505	0.0892	CbGbCtD
Albendazole—CYP1A2—Etoposide—urinary bladder cancer	0.0421	0.0745	CbGbCtD
Albendazole—ABCB1—Cisplatin—urinary bladder cancer	0.0375	0.0663	CbGbCtD
Albendazole—ABCB1—Etoposide—urinary bladder cancer	0.0368	0.0651	CbGbCtD
Albendazole—ABCB1—Doxorubicin—urinary bladder cancer	0.0251	0.0444	CbGbCtD
Albendazole—ABCB1—Methotrexate—urinary bladder cancer	0.0243	0.043	CbGbCtD
Albendazole—CYP3A4—Etoposide—urinary bladder cancer	0.0221	0.039	CbGbCtD
Albendazole—CYP3A4—Doxorubicin—urinary bladder cancer	0.0151	0.0266	CbGbCtD
Albendazole—Alopecia reversible—Gemcitabine—urinary bladder cancer	0.00971	0.0526	CcSEcCtD
Albendazole—CYP1A2—urine—urinary bladder cancer	0.0083	0.0741	CbGeAlD
Albendazole—Alopecia reversible—Etoposide—urinary bladder cancer	0.0083	0.0449	CcSEcCtD
Albendazole—TUBA1A—Zalcitabine—Gemcitabine—urinary bladder cancer	0.0081	0.826	CbGdCrCtD
Albendazole—TUBA1A—prostate gland—urinary bladder cancer	0.00788	0.0703	CbGeAlD
Albendazole—TUBA1A—seminal vesicle—urinary bladder cancer	0.00666	0.0594	CbGeAlD
Albendazole—CYP3A4—urine—urinary bladder cancer	0.00601	0.0536	CbGeAlD
Albendazole—TUBA1A—epithelium—urinary bladder cancer	0.00579	0.0516	CbGeAlD
Albendazole—TUBA1A—smooth muscle tissue—urinary bladder cancer	0.00558	0.0498	CbGeAlD
Albendazole—TUBA1A—renal system—urinary bladder cancer	0.00537	0.0479	CbGeAlD
Albendazole—TUBA1A—urethra—urinary bladder cancer	0.00527	0.0471	CbGeAlD
Albendazole—TUBB4B—prostate gland—urinary bladder cancer	0.00525	0.0468	CbGeAlD
Albendazole—Alopecia reversible—Epirubicin—urinary bladder cancer	0.00465	0.0252	CcSEcCtD
Albendazole—TUBB4B—seminal vesicle—urinary bladder cancer	0.00444	0.0396	CbGeAlD
Albendazole—Alopecia reversible—Doxorubicin—urinary bladder cancer	0.0043	0.0233	CcSEcCtD
Albendazole—TUBA1A—female reproductive system—urinary bladder cancer	0.0043	0.0384	CbGeAlD
Albendazole—TUBA1A—vagina—urinary bladder cancer	0.00389	0.0347	CbGeAlD
Albendazole—TUBB4B—smooth muscle tissue—urinary bladder cancer	0.00372	0.0332	CbGeAlD
Albendazole—TUBB4B—renal system—urinary bladder cancer	0.00358	0.0319	CbGeAlD
Albendazole—TUBB4B—urethra—urinary bladder cancer	0.00352	0.0314	CbGeAlD
Albendazole—Pancytopenia—Mitomycin—urinary bladder cancer	0.00311	0.0168	CcSEcCtD
Albendazole—TUBB4B—female reproductive system—urinary bladder cancer	0.00287	0.0256	CbGeAlD
Albendazole—TUBB4B—vagina—urinary bladder cancer	0.00259	0.0231	CbGeAlD
Albendazole—TUBA1A—lymph node—urinary bladder cancer	0.00252	0.0224	CbGeAlD
Albendazole—Alopecia—Mitomycin—urinary bladder cancer	0.00231	0.0125	CcSEcCtD
Albendazole—Gastrointestinal pain—Valrubicin—urinary bladder cancer	0.00221	0.012	CcSEcCtD
Albendazole—CYP1A1—epithelium—urinary bladder cancer	0.00216	0.0193	CbGeAlD
Albendazole—Abdominal pain—Valrubicin—urinary bladder cancer	0.00213	0.0116	CcSEcCtD
Albendazole—Body temperature increased—Valrubicin—urinary bladder cancer	0.00213	0.0116	CcSEcCtD
Albendazole—Leukopenia—Mitomycin—urinary bladder cancer	0.00204	0.0111	CcSEcCtD
Albendazole—CYP1A2—renal system—urinary bladder cancer	0.00203	0.0181	CbGeAlD
Albendazole—CYP1A1—renal system—urinary bladder cancer	0.002	0.0179	CbGeAlD
Albendazole—Body temperature increased—Carboplatin—urinary bladder cancer	0.00198	0.0107	CcSEcCtD
Albendazole—CYP1A1—urethra—urinary bladder cancer	0.00197	0.0176	CbGeAlD
Albendazole—Thrombocytopenia—Mitomycin—urinary bladder cancer	0.00182	0.00987	CcSEcCtD
Albendazole—Dizziness—Valrubicin—urinary bladder cancer	0.00179	0.00967	CcSEcCtD
Albendazole—Vomiting—Valrubicin—urinary bladder cancer	0.00172	0.0093	CcSEcCtD
Albendazole—Rash—Valrubicin—urinary bladder cancer	0.0017	0.00922	CcSEcCtD
Albendazole—TUBA1A—Azacitidine—Gemcitabine—urinary bladder cancer	0.0017	0.174	CbGdCrCtD
Albendazole—Dermatitis—Valrubicin—urinary bladder cancer	0.0017	0.00921	CcSEcCtD
Albendazole—Headache—Valrubicin—urinary bladder cancer	0.00169	0.00916	CcSEcCtD
Albendazole—TUBB4B—lymph node—urinary bladder cancer	0.00168	0.015	CbGeAlD
Albendazole—Renal failure acute—Cisplatin—urinary bladder cancer	0.00162	0.00876	CcSEcCtD
Albendazole—CYP1A1—female reproductive system—urinary bladder cancer	0.0016	0.0143	CbGeAlD
Albendazole—Nausea—Valrubicin—urinary bladder cancer	0.0016	0.00869	CcSEcCtD
Albendazole—Pancytopenia—Thiotepa—urinary bladder cancer	0.00156	0.00846	CcSEcCtD
Albendazole—ABCB1—prostate gland—urinary bladder cancer	0.00153	0.0136	CbGeAlD
Albendazole—Liver function test abnormal—Gemcitabine—urinary bladder cancer	0.00148	0.00801	CcSEcCtD
Albendazole—CYP3A4—renal system—urinary bladder cancer	0.00147	0.0131	CbGeAlD
Albendazole—Body temperature increased—Mitomycin—urinary bladder cancer	0.00147	0.00797	CcSEcCtD
Albendazole—CYP1A1—vagina—urinary bladder cancer	0.00145	0.0129	CbGeAlD
Albendazole—Hepatobiliary disease—Thiotepa—urinary bladder cancer	0.00139	0.00751	CcSEcCtD
Albendazole—Agranulocytosis—Thiotepa—urinary bladder cancer	0.00137	0.00741	CcSEcCtD
Albendazole—Pancytopenia—Gemcitabine—urinary bladder cancer	0.00131	0.00712	CcSEcCtD
Albendazole—Urinary tract disorder—Thiotepa—urinary bladder cancer	0.0013	0.00704	CcSEcCtD
Albendazole—Neutropenia—Gemcitabine—urinary bladder cancer	0.00129	0.00701	CcSEcCtD
Albendazole—Pancytopenia—Fluorouracil—urinary bladder cancer	0.00129	0.007	CcSEcCtD
Albendazole—ABCB1—seminal vesicle—urinary bladder cancer	0.00129	0.0115	CbGeAlD
Albendazole—Urethral disorder—Thiotepa—urinary bladder cancer	0.00129	0.00699	CcSEcCtD
Albendazole—Dizziness—Mitomycin—urinary bladder cancer	0.00123	0.00666	CcSEcCtD
Albendazole—Pancytopenia—Cisplatin—urinary bladder cancer	0.00122	0.00664	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Gemcitabine—urinary bladder cancer	0.00122	0.00663	CcSEcCtD
Albendazole—Immune system disorder—Thiotepa—urinary bladder cancer	0.00119	0.00644	CcSEcCtD
Albendazole—Vomiting—Mitomycin—urinary bladder cancer	0.00118	0.00641	CcSEcCtD
Albendazole—CYP3A4—female reproductive system—urinary bladder cancer	0.00118	0.0105	CbGeAlD
Albendazole—Rash—Mitomycin—urinary bladder cancer	0.00117	0.00635	CcSEcCtD
Albendazole—Dermatitis—Mitomycin—urinary bladder cancer	0.00117	0.00635	CcSEcCtD
Albendazole—Hepatobiliary disease—Gemcitabine—urinary bladder cancer	0.00117	0.00632	CcSEcCtD
Albendazole—Headache—Mitomycin—urinary bladder cancer	0.00117	0.00631	CcSEcCtD
Albendazole—Alopecia—Thiotepa—urinary bladder cancer	0.00116	0.0063	CcSEcCtD
Albendazole—Agranulocytosis—Gemcitabine—urinary bladder cancer	0.00115	0.00624	CcSEcCtD
Albendazole—Agranulocytosis—Fluorouracil—urinary bladder cancer	0.00113	0.00613	CcSEcCtD
Albendazole—ABCB1—epithelium—urinary bladder cancer	0.00112	0.01	CbGeAlD
Albendazole—Pancytopenia—Etoposide—urinary bladder cancer	0.00112	0.00608	CcSEcCtD
Albendazole—Neutropenia—Etoposide—urinary bladder cancer	0.0011	0.00599	CcSEcCtD
Albendazole—Nausea—Mitomycin—urinary bladder cancer	0.0011	0.00599	CcSEcCtD
Albendazole—Urinary tract disorder—Gemcitabine—urinary bladder cancer	0.00109	0.00593	CcSEcCtD
Albendazole—Hepatobiliary disease—Cisplatin—urinary bladder cancer	0.00109	0.00589	CcSEcCtD
Albendazole—Urethral disorder—Gemcitabine—urinary bladder cancer	0.00109	0.00588	CcSEcCtD
Albendazole—Aplastic anaemia—Methotrexate—urinary bladder cancer	0.00106	0.00574	CcSEcCtD
Albendazole—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.00105	0.00567	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.00104	0.00566	CcSEcCtD
Albendazole—ABCB1—renal system—urinary bladder cancer	0.00104	0.00929	CbGeAlD
Albendazole—Leukopenia—Thiotepa—urinary bladder cancer	0.00103	0.00556	CcSEcCtD
Albendazole—ABCB1—urethra—urinary bladder cancer	0.00102	0.00912	CbGeAlD
Albendazole—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.00102	0.00552	CcSEcCtD
Albendazole—Urethral disorder—Cisplatin—urinary bladder cancer	0.00101	0.00548	CcSEcCtD
Albendazole—Immune system disorder—Gemcitabine—urinary bladder cancer	0.001	0.00542	CcSEcCtD
Albendazole—Hepatobiliary disease—Etoposide—urinary bladder cancer	0.000996	0.0054	CcSEcCtD
Albendazole—Aplastic anaemia—Epirubicin—urinary bladder cancer	0.000991	0.00537	CcSEcCtD
Albendazole—Agranulocytosis—Etoposide—urinary bladder cancer	0.000983	0.00533	CcSEcCtD
Albendazole—Alopecia—Gemcitabine—urinary bladder cancer	0.000979	0.0053	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000969	0.00525	CcSEcCtD
Albendazole—Alopecia—Fluorouracil—urinary bladder cancer	0.000962	0.00521	CcSEcCtD
Albendazole—CYP1A1—lymph node—urinary bladder cancer	0.000939	0.00838	CbGeAlD
Albendazole—Urinary tract disorder—Etoposide—urinary bladder cancer	0.000934	0.00506	CcSEcCtD
Albendazole—Immune system disorder—Cisplatin—urinary bladder cancer	0.000932	0.00505	CcSEcCtD
Albendazole—Urethral disorder—Etoposide—urinary bladder cancer	0.000927	0.00502	CcSEcCtD
Albendazole—Aplastic anaemia—Doxorubicin—urinary bladder cancer	0.000917	0.00497	CcSEcCtD
Albendazole—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000916	0.00496	CcSEcCtD
Albendazole—Alopecia—Cisplatin—urinary bladder cancer	0.000912	0.00494	CcSEcCtD
Albendazole—Skin disorder—Thiotepa—urinary bladder cancer	0.000909	0.00492	CcSEcCtD
Albendazole—Erythema multiforme—Etoposide—urinary bladder cancer	0.000894	0.00484	CcSEcCtD
Albendazole—Renal failure acute—Methotrexate—urinary bladder cancer	0.000887	0.0048	CcSEcCtD
Albendazole—Leukopenia—Gemcitabine—urinary bladder cancer	0.000863	0.00468	CcSEcCtD
Albendazole—Immune system disorder—Etoposide—urinary bladder cancer	0.000854	0.00463	CcSEcCtD
Albendazole—Leukopenia—Fluorouracil—urinary bladder cancer	0.000849	0.0046	CcSEcCtD
Albendazole—Alopecia—Etoposide—urinary bladder cancer	0.000836	0.00453	CcSEcCtD
Albendazole—ABCB1—female reproductive system—urinary bladder cancer	0.000834	0.00744	CbGeAlD
Albendazole—Renal failure acute—Epirubicin—urinary bladder cancer	0.00083	0.0045	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000815	0.00442	CcSEcCtD
Albendazole—Leukopenia—Cisplatin—urinary bladder cancer	0.000804	0.00436	CcSEcCtD
Albendazole—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.00077	0.00417	CcSEcCtD
Albendazole—Renal failure acute—Doxorubicin—urinary bladder cancer	0.000768	0.00416	CcSEcCtD
Albendazole—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000765	0.00414	CcSEcCtD
Albendazole—Skin disorder—Gemcitabine—urinary bladder cancer	0.000764	0.00414	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00076	0.00412	CcSEcCtD
Albendazole—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000757	0.0041	CcSEcCtD
Albendazole—Liver function test abnormal—Methotrexate—urinary bladder cancer	0.000756	0.0041	CcSEcCtD
Albendazole—ABCB1—vagina—urinary bladder cancer	0.000754	0.00673	CbGeAlD
Albendazole—Urticaria—Thiotepa—urinary bladder cancer	0.000743	0.00403	CcSEcCtD
Albendazole—Vertigo—Etoposide—urinary bladder cancer	0.00074	0.00401	CcSEcCtD
Albendazole—Abdominal pain—Thiotepa—urinary bladder cancer	0.000739	0.00401	CcSEcCtD
Albendazole—Body temperature increased—Thiotepa—urinary bladder cancer	0.000739	0.00401	CcSEcCtD
Albendazole—Leukopenia—Etoposide—urinary bladder cancer	0.000737	0.00399	CcSEcCtD
Albendazole—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000718	0.00389	CcSEcCtD
Albendazole—Skin disorder—Cisplatin—urinary bladder cancer	0.000712	0.00386	CcSEcCtD
Albendazole—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.000707	0.00383	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000696	0.00377	CcSEcCtD
Albendazole—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000689	0.00373	CcSEcCtD
Albendazole—Pancytopenia—Methotrexate—urinary bladder cancer	0.000672	0.00364	CcSEcCtD
Albendazole—Neutropenia—Methotrexate—urinary bladder cancer	0.000662	0.00359	CcSEcCtD
Albendazole—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000658	0.00356	CcSEcCtD
Albendazole—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000655	0.00355	CcSEcCtD
Albendazole—Skin disorder—Etoposide—urinary bladder cancer	0.000653	0.00354	CcSEcCtD
Albendazole—Pancytopenia—Epirubicin—urinary bladder cancer	0.000629	0.00341	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000626	0.00339	CcSEcCtD
Albendazole—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000622	0.00337	CcSEcCtD
Albendazole—Neutropenia—Epirubicin—urinary bladder cancer	0.000619	0.00336	CcSEcCtD
Albendazole—Dizziness—Thiotepa—urinary bladder cancer	0.000619	0.00335	CcSEcCtD
Albendazole—Urticaria—Fluorouracil—urinary bladder cancer	0.000615	0.00333	CcSEcCtD
Albendazole—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000612	0.00331	CcSEcCtD
Albendazole—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000597	0.00323	CcSEcCtD
Albendazole—Vomiting—Thiotepa—urinary bladder cancer	0.000595	0.00322	CcSEcCtD
Albendazole—Rash—Thiotepa—urinary bladder cancer	0.00059	0.0032	CcSEcCtD
Albendazole—Dermatitis—Thiotepa—urinary bladder cancer	0.000589	0.00319	CcSEcCtD
Albendazole—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000589	0.00319	CcSEcCtD
Albendazole—Headache—Thiotepa—urinary bladder cancer	0.000586	0.00317	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000585	0.00317	CcSEcCtD
Albendazole—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000582	0.00315	CcSEcCtD
Albendazole—Body temperature increased—Cisplatin—urinary bladder cancer	0.00058	0.00314	CcSEcCtD
Albendazole—Neutropenia—Doxorubicin—urinary bladder cancer	0.000573	0.0031	CcSEcCtD
Albendazole—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00057	0.00309	CcSEcCtD
Albendazole—Hepatitis—Methotrexate—urinary bladder cancer	0.000566	0.00307	CcSEcCtD
Albendazole—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000559	0.00303	CcSEcCtD
Albendazole—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000558	0.00303	CcSEcCtD
Albendazole—Nausea—Thiotepa—urinary bladder cancer	0.000556	0.00301	CcSEcCtD
Albendazole—Urethral disorder—Methotrexate—urinary bladder cancer	0.000555	0.00301	CcSEcCtD
Albendazole—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000551	0.00299	CcSEcCtD
Albendazole—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000549	0.00298	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000542	0.00293	CcSEcCtD
Albendazole—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00054	0.00293	CcSEcCtD
Albendazole—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000536	0.0029	CcSEcCtD
Albendazole—Urticaria—Etoposide—urinary bladder cancer	0.000534	0.00289	CcSEcCtD
Albendazole—Body temperature increased—Etoposide—urinary bladder cancer	0.000531	0.00288	CcSEcCtD
Albendazole—Abdominal pain—Etoposide—urinary bladder cancer	0.000531	0.00288	CcSEcCtD
Albendazole—Hepatitis—Epirubicin—urinary bladder cancer	0.00053	0.00287	CcSEcCtD
Albendazole—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000524	0.00284	CcSEcCtD
Albendazole—Urethral disorder—Epirubicin—urinary bladder cancer	0.00052	0.00282	CcSEcCtD
Albendazole—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000517	0.0028	CcSEcCtD
Albendazole—Immune system disorder—Methotrexate—urinary bladder cancer	0.000512	0.00277	CcSEcCtD
Albendazole—Dizziness—Fluorouracil—urinary bladder cancer	0.000512	0.00277	CcSEcCtD
Albendazole—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.00051	0.00276	CcSEcCtD
Albendazole—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000501	0.00272	CcSEcCtD
Albendazole—Alopecia—Methotrexate—urinary bladder cancer	0.000501	0.00271	CcSEcCtD
Albendazole—Vomiting—Gemcitabine—urinary bladder cancer	0.0005	0.00271	CcSEcCtD
Albendazole—Rash—Gemcitabine—urinary bladder cancer	0.000496	0.00269	CcSEcCtD
Albendazole—Dermatitis—Gemcitabine—urinary bladder cancer	0.000496	0.00269	CcSEcCtD
Albendazole—Hypersensitivity—Etoposide—urinary bladder cancer	0.000495	0.00268	CcSEcCtD
Albendazole—Headache—Gemcitabine—urinary bladder cancer	0.000493	0.00267	CcSEcCtD
Albendazole—Vomiting—Fluorouracil—urinary bladder cancer	0.000492	0.00266	CcSEcCtD
Albendazole—Hepatitis—Doxorubicin—urinary bladder cancer	0.000491	0.00266	CcSEcCtD
Albendazole—Rash—Fluorouracil—urinary bladder cancer	0.000488	0.00264	CcSEcCtD
Albendazole—ABCB1—lymph node—urinary bladder cancer	0.000488	0.00435	CbGeAlD
Albendazole—Dermatitis—Fluorouracil—urinary bladder cancer	0.000487	0.00264	CcSEcCtD
Albendazole—Headache—Fluorouracil—urinary bladder cancer	0.000485	0.00263	CcSEcCtD
Albendazole—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000484	0.00262	CcSEcCtD
Albendazole—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000481	0.0026	CcSEcCtD
Albendazole—Immune system disorder—Epirubicin—urinary bladder cancer	0.000479	0.00259	CcSEcCtD
Albendazole—Alopecia—Epirubicin—urinary bladder cancer	0.000468	0.00254	CcSEcCtD
Albendazole—Nausea—Gemcitabine—urinary bladder cancer	0.000467	0.00253	CcSEcCtD
Albendazole—Vomiting—Cisplatin—urinary bladder cancer	0.000466	0.00253	CcSEcCtD
Albendazole—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000464	0.00251	CcSEcCtD
Albendazole—Rash—Cisplatin—urinary bladder cancer	0.000462	0.00251	CcSEcCtD
Albendazole—Dermatitis—Cisplatin—urinary bladder cancer	0.000462	0.0025	CcSEcCtD
Albendazole—Nausea—Fluorouracil—urinary bladder cancer	0.00046	0.00249	CcSEcCtD
Albendazole—Dizziness—Etoposide—urinary bladder cancer	0.000444	0.00241	CcSEcCtD
Albendazole—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000443	0.0024	CcSEcCtD
Albendazole—Vertigo—Methotrexate—urinary bladder cancer	0.000443	0.0024	CcSEcCtD
Albendazole—Leukopenia—Methotrexate—urinary bladder cancer	0.000441	0.00239	CcSEcCtD
Albendazole—Nausea—Cisplatin—urinary bladder cancer	0.000436	0.00236	CcSEcCtD
Albendazole—Alopecia—Doxorubicin—urinary bladder cancer	0.000433	0.00235	CcSEcCtD
Albendazole—Vomiting—Etoposide—urinary bladder cancer	0.000427	0.00231	CcSEcCtD
Albendazole—Rash—Etoposide—urinary bladder cancer	0.000424	0.0023	CcSEcCtD
Albendazole—Dermatitis—Etoposide—urinary bladder cancer	0.000423	0.00229	CcSEcCtD
Albendazole—Headache—Etoposide—urinary bladder cancer	0.000421	0.00228	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000417	0.00226	CcSEcCtD
Albendazole—Vertigo—Epirubicin—urinary bladder cancer	0.000415	0.00225	CcSEcCtD
Albendazole—Leukopenia—Epirubicin—urinary bladder cancer	0.000413	0.00224	CcSEcCtD
Albendazole—Nausea—Etoposide—urinary bladder cancer	0.000399	0.00216	CcSEcCtD
Albendazole—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000394	0.00213	CcSEcCtD
Albendazole—Skin disorder—Methotrexate—urinary bladder cancer	0.000391	0.00212	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00039	0.00211	CcSEcCtD
Albendazole—Vertigo—Doxorubicin—urinary bladder cancer	0.000384	0.00208	CcSEcCtD
Albendazole—Leukopenia—Doxorubicin—urinary bladder cancer	0.000382	0.00207	CcSEcCtD
Albendazole—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000369	0.002	CcSEcCtD
Albendazole—Skin disorder—Epirubicin—urinary bladder cancer	0.000366	0.00198	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000361	0.00196	CcSEcCtD
Albendazole—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000341	0.00185	CcSEcCtD
Albendazole—Skin disorder—Doxorubicin—urinary bladder cancer	0.000338	0.00183	CcSEcCtD
Albendazole—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000329	0.00178	CcSEcCtD
Albendazole—Urticaria—Methotrexate—urinary bladder cancer	0.00032	0.00173	CcSEcCtD
Albendazole—Abdominal pain—Methotrexate—urinary bladder cancer	0.000318	0.00172	CcSEcCtD
Albendazole—Body temperature increased—Methotrexate—urinary bladder cancer	0.000318	0.00172	CcSEcCtD
Albendazole—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000308	0.00167	CcSEcCtD
Albendazole—Urticaria—Epirubicin—urinary bladder cancer	0.000299	0.00162	CcSEcCtD
Albendazole—Abdominal pain—Epirubicin—urinary bladder cancer	0.000298	0.00161	CcSEcCtD
Albendazole—Body temperature increased—Epirubicin—urinary bladder cancer	0.000298	0.00161	CcSEcCtD
Albendazole—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000297	0.00161	CcSEcCtD
Albendazole—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000285	0.00154	CcSEcCtD
Albendazole—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000277	0.0015	CcSEcCtD
Albendazole—Urticaria—Doxorubicin—urinary bladder cancer	0.000277	0.0015	CcSEcCtD
Albendazole—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000275	0.00149	CcSEcCtD
Albendazole—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000275	0.00149	CcSEcCtD
Albendazole—Dizziness—Methotrexate—urinary bladder cancer	0.000266	0.00144	CcSEcCtD
Albendazole—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000257	0.00139	CcSEcCtD
Albendazole—Vomiting—Methotrexate—urinary bladder cancer	0.000256	0.00139	CcSEcCtD
Albendazole—Rash—Methotrexate—urinary bladder cancer	0.000254	0.00137	CcSEcCtD
Albendazole—Dermatitis—Methotrexate—urinary bladder cancer	0.000254	0.00137	CcSEcCtD
Albendazole—Headache—Methotrexate—urinary bladder cancer	0.000252	0.00137	CcSEcCtD
Albendazole—Dizziness—Epirubicin—urinary bladder cancer	0.000249	0.00135	CcSEcCtD
Albendazole—Vomiting—Epirubicin—urinary bladder cancer	0.000239	0.0013	CcSEcCtD
Albendazole—Nausea—Methotrexate—urinary bladder cancer	0.000239	0.0013	CcSEcCtD
Albendazole—Rash—Epirubicin—urinary bladder cancer	0.000237	0.00129	CcSEcCtD
Albendazole—Dermatitis—Epirubicin—urinary bladder cancer	0.000237	0.00129	CcSEcCtD
Albendazole—Headache—Epirubicin—urinary bladder cancer	0.000236	0.00128	CcSEcCtD
Albendazole—Dizziness—Doxorubicin—urinary bladder cancer	0.00023	0.00125	CcSEcCtD
Albendazole—Nausea—Epirubicin—urinary bladder cancer	0.000224	0.00121	CcSEcCtD
Albendazole—Vomiting—Doxorubicin—urinary bladder cancer	0.000222	0.0012	CcSEcCtD
Albendazole—Rash—Doxorubicin—urinary bladder cancer	0.00022	0.00119	CcSEcCtD
Albendazole—Dermatitis—Doxorubicin—urinary bladder cancer	0.00022	0.00119	CcSEcCtD
Albendazole—Headache—Doxorubicin—urinary bladder cancer	0.000218	0.00118	CcSEcCtD
Albendazole—Nausea—Doxorubicin—urinary bladder cancer	0.000207	0.00112	CcSEcCtD
Albendazole—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.000201	0.00157	CbGpPWpGaD
Albendazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.0002	0.00157	CbGpPWpGaD
Albendazole—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000198	0.00155	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000195	0.00153	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	0.000187	0.00147	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000185	0.00145	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—RB1—urinary bladder cancer	0.000185	0.00145	CbGpPWpGaD
Albendazole—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000184	0.00144	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	0.000184	0.00144	CbGpPWpGaD
Albendazole—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	0.000184	0.00144	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000184	0.00144	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000182	0.00143	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000182	0.00142	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	0.000181	0.00142	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000178	0.0014	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000178	0.0014	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.00017	0.00133	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.00017	0.00133	CbGpPWpGaD
Albendazole—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000169	0.00133	CbGpPWpGaD
Albendazole—CYP1A1—Biological oxidations—GSTP1—urinary bladder cancer	0.000169	0.00132	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000168	0.00132	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—CCNE1—urinary bladder cancer	0.000167	0.00131	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000167	0.00131	CbGpPWpGaD
Albendazole—CYP1A1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000167	0.00131	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—TYMS—urinary bladder cancer	0.000164	0.00129	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—CDKN2A—urinary bladder cancer	0.000162	0.00127	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.00016	0.00126	CbGpPWpGaD
Albendazole—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.00016	0.00126	CbGpPWpGaD
Albendazole—CYP1A1—PPARA activates gene expression—PPARG—urinary bladder cancer	0.000159	0.00125	CbGpPWpGaD
Albendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—urinary bladder cancer	0.000156	0.00122	CbGpPWpGaD
Albendazole—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000156	0.00122	CbGpPWpGaD
Albendazole—CYP1A1—Biological oxidations—GSTM1—urinary bladder cancer	0.000155	0.00122	CbGpPWpGaD
Albendazole—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000155	0.00121	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	0.000153	0.0012	CbGpPWpGaD
Albendazole—CYP1A1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000153	0.0012	CbGpPWpGaD
Albendazole—CYP1A1—PPARA activates gene expression—CREBBP—urinary bladder cancer	0.000153	0.0012	CbGpPWpGaD
Albendazole—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000153	0.0012	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—IGF1—urinary bladder cancer	0.000153	0.0012	CbGpPWpGaD
Albendazole—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.00015	0.00118	CbGpPWpGaD
Albendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—NCOR1—urinary bladder cancer	0.00015	0.00117	CbGpPWpGaD
Albendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CREBBP—urinary bladder cancer	0.00015	0.00117	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000149	0.00116	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	0.000148	0.00116	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000148	0.00116	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	0.000143	0.00112	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—TERT—urinary bladder cancer	0.000143	0.00112	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000143	0.00112	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—EP300—urinary bladder cancer	0.000141	0.00111	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.00014	0.0011	CbGpPWpGaD
Albendazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	0.000138	0.00108	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—CCND1—urinary bladder cancer	0.000137	0.00107	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000133	0.00105	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000133	0.00105	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—CDKN1A—urinary bladder cancer	0.000133	0.00104	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.00013	0.00102	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.00013	0.00102	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—ATM—urinary bladder cancer	0.000129	0.00101	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—CDK4—urinary bladder cancer	0.000128	0.001	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	0.000126	0.00099	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—EP300—urinary bladder cancer	0.000126	0.000989	CbGpPWpGaD
Albendazole—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	0.000125	0.000981	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—RB1—urinary bladder cancer	0.000125	0.000977	CbGpPWpGaD
Albendazole—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000124	0.000969	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—MYC—urinary bladder cancer	0.000123	0.000964	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—CXCL8—urinary bladder cancer	0.000123	0.000961	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000121	0.000948	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	0.000121	0.000947	CbGpPWpGaD
Albendazole—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.00012	0.00094	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000118	0.000921	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000116	0.000911	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000116	0.000907	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000115	0.000904	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000114	0.000891	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000114	0.000891	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—RB1—urinary bladder cancer	0.000111	0.000873	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—MYC—urinary bladder cancer	0.00011	0.000862	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	0.00011	0.000859	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000108	0.000848	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000108	0.000848	CbGpPWpGaD
Albendazole—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000108	0.000845	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000107	0.000842	CbGpPWpGaD
Albendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—urinary bladder cancer	0.000107	0.000841	CbGpPWpGaD
Albendazole—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000106	0.000833	CbGpPWpGaD
Albendazole—CYP1A1—PPARA activates gene expression—EP300—urinary bladder cancer	0.000104	0.000816	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—GSTZ1—urinary bladder cancer	0.000104	0.000811	CbGpPWpGaD
Albendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—urinary bladder cancer	0.000103	0.000808	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000103	0.000804	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.000102	0.000801	CbGpPWpGaD
Albendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—urinary bladder cancer	0.000102	0.000799	CbGpPWpGaD
Albendazole—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	9.9e-05	0.000776	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	9.87e-05	0.000773	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—GSTO2—urinary bladder cancer	9.82e-05	0.000769	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—NAT1—urinary bladder cancer	9.82e-05	0.000769	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—CDKN2A—urinary bladder cancer	9.8e-05	0.000768	CbGpPWpGaD
Albendazole—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	9.77e-05	0.000765	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	9.66e-05	0.000757	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	9.26e-05	0.000725	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—IGF1—urinary bladder cancer	9.21e-05	0.000722	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	9.13e-05	0.000715	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	9.04e-05	0.000708	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—TP53—urinary bladder cancer	9.03e-05	0.000708	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	9e-05	0.000705	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—UGT2B7—urinary bladder cancer	8.98e-05	0.000703	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	8.96e-05	0.000702	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	8.96e-05	0.000702	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	8.8e-05	0.000689	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—EP300—urinary bladder cancer	8.52e-05	0.000668	CbGpPWpGaD
Albendazole—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	8.32e-05	0.000652	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—CCND1—urinary bladder cancer	8.28e-05	0.000649	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	8.27e-05	0.000648	CbGpPWpGaD
Albendazole—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	8.2e-05	0.000643	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—CYP4B1—urinary bladder cancer	8.08e-05	0.000633	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—CDKN1A—urinary bladder cancer	8.01e-05	0.000627	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	7.86e-05	0.000615	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—GSTO2—urinary bladder cancer	7.84e-05	0.000614	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—NAT1—urinary bladder cancer	7.84e-05	0.000614	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	7.76e-05	0.000608	CbGpPWpGaD
Albendazole—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	7.64e-05	0.000599	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—SLC19A1—urinary bladder cancer	7.63e-05	0.000598	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—EP300—urinary bladder cancer	7.62e-05	0.000597	CbGpPWpGaD
Albendazole—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.54e-05	0.000591	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—PRSS3—urinary bladder cancer	7.44e-05	0.000583	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—MYC—urinary bladder cancer	7.43e-05	0.000582	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—CXCL8—urinary bladder cancer	7.41e-05	0.00058	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	7.17e-05	0.000562	CbGpPWpGaD
Albendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	7.02e-05	0.00055	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	6.66e-05	0.000522	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—MYC—urinary bladder cancer	6.64e-05	0.00052	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	6.6e-05	0.000517	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	6.58e-05	0.000515	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	6.46e-05	0.000506	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	6.43e-05	0.000504	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	6.26e-05	0.00049	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—NAT1—urinary bladder cancer	6.26e-05	0.00049	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.16e-05	0.000482	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	6.1e-05	0.000478	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.97e-05	0.000467	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—TYMP—urinary bladder cancer	5.95e-05	0.000466	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—PRSS3—urinary bladder cancer	5.94e-05	0.000466	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	5.81e-05	0.000455	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	5.72e-05	0.000449	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.71e-05	0.000448	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	5.62e-05	0.000441	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	5.61e-05	0.00044	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—TP53—urinary bladder cancer	5.45e-05	0.000427	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—NAT2—urinary bladder cancer	5.38e-05	0.000421	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	5.35e-05	0.000419	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	5.2e-05	0.000408	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	5.15e-05	0.000404	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	5.1e-05	0.000399	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	4.87e-05	0.000381	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	4.83e-05	0.000378	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—NAT1—urinary bladder cancer	4.83e-05	0.000378	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—TYMP—urinary bladder cancer	4.75e-05	0.000372	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	4.74e-05	0.000372	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	4.66e-05	0.000365	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—RRM2—urinary bladder cancer	4.64e-05	0.000364	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	4.56e-05	0.000357	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.42e-05	0.000346	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	4.34e-05	0.00034	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	4.31e-05	0.000337	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—HPGDS—urinary bladder cancer	4.3e-05	0.000337	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—ENO2—urinary bladder cancer	4.3e-05	0.000337	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—NAT2—urinary bladder cancer	4.3e-05	0.000337	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.27e-05	0.000335	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—GSTT1—urinary bladder cancer	4.17e-05	0.000327	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.11e-05	0.000322	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.98e-05	0.000312	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.83e-05	0.0003	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.8e-05	0.000298	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—TYMP—urinary bladder cancer	3.79e-05	0.000297	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.76e-05	0.000294	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—RRM2—urinary bladder cancer	3.71e-05	0.000291	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.66e-05	0.000287	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.64e-05	0.000285	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—NQO1—urinary bladder cancer	3.47e-05	0.000272	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—ENO2—urinary bladder cancer	3.43e-05	0.000269	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—HPGDS—urinary bladder cancer	3.43e-05	0.000269	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—NAT2—urinary bladder cancer	3.43e-05	0.000269	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.36e-05	0.000263	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—GSTT1—urinary bladder cancer	3.33e-05	0.000261	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.12e-05	0.000244	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—RRM2—urinary bladder cancer	2.96e-05	0.000232	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.93e-05	0.00023	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.93e-05	0.000229	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	2.89e-05	0.000227	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.8e-05	0.000219	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—NQO1—urinary bladder cancer	2.77e-05	0.000217	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	2.74e-05	0.000215	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—ENO2—urinary bladder cancer	2.74e-05	0.000215	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.73e-05	0.000214	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—TYMS—urinary bladder cancer	2.69e-05	0.000211	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	2.66e-05	0.000208	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	2.66e-05	0.000208	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	2.66e-05	0.000208	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.65e-05	0.000207	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.62e-05	0.000205	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—GPX1—urinary bladder cancer	2.54e-05	0.000199	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	2.5e-05	0.000196	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	2.35e-05	0.000184	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—GSTP1—urinary bladder cancer	2.31e-05	0.000181	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.28e-05	0.000179	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—NQO1—urinary bladder cancer	2.21e-05	0.000173	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—TYMS—urinary bladder cancer	2.15e-05	0.000168	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.14e-05	0.000168	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—GSTM1—urinary bladder cancer	2.12e-05	0.000166	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—NCOR1—urinary bladder cancer	2.12e-05	0.000166	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.12e-05	0.000166	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.12e-05	0.000166	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.05e-05	0.000161	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—GPX1—urinary bladder cancer	2.03e-05	0.000159	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.99e-05	0.000156	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—PPARG—urinary bladder cancer	1.9e-05	0.000149	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.88e-05	0.000147	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.87e-05	0.000147	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.84e-05	0.000144	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	1.83e-05	0.000143	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.78e-05	0.00014	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.71e-05	0.000134	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.71e-05	0.000134	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.69e-05	0.000133	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.69e-05	0.000133	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.62e-05	0.000127	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.59e-05	0.000125	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.52e-05	0.000119	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	1.5e-05	0.000117	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.5e-05	0.000117	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.46e-05	0.000114	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.42e-05	0.000111	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.32e-05	0.000104	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.31e-05	0.000102	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.31e-05	0.000102	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—PTEN—urinary bladder cancer	1.31e-05	0.000102	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.25e-05	9.81e-05	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—EP300—urinary bladder cancer	1.25e-05	9.76e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.23e-05	9.63e-05	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.21e-05	9.51e-05	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.2e-05	9.37e-05	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.17e-05	9.14e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.16e-05	9.05e-05	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—PTEN—urinary bladder cancer	1.04e-05	8.17e-05	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—EP300—urinary bladder cancer	9.95e-06	7.79e-05	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	9.55e-06	7.48e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—PPARG—urinary bladder cancer	9.37e-06	7.34e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	9e-06	7.05e-05	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—PTEN—urinary bladder cancer	8.33e-06	6.53e-05	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—EP300—urinary bladder cancer	7.94e-06	6.22e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	7.37e-06	5.77e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—PTEN—urinary bladder cancer	6.43e-06	5.04e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—EP300—urinary bladder cancer	6.13e-06	4.8e-05	CbGpPWpGaD
